increased heart rate with tirzepatide and Cardiovascular Outcomes: A Narrative Review of Mechanisms, Efficacy and Implications for Failure Management - Abdul‐Hafez - 2026 - Endocrinology, Diabetes & Metabolism What to Expect on Tirzepatide:

Vitamin B-12 is for injection only

The SELECT trial (Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity), a phase 3 study involving 17,604 adults with overweight or obesity and pre-existing CVD but no diabetes, revealed that once-weekly subcutaneous semaglutide 2.4 mg reduced the risk of major adverse cardiovascular events by 20% compared with placebo over a mean follow-up of 39.8 months, including cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke [48]

& Yarnitsky, D

Dutta M, Singh B, Joshi M, Das D, Subramani E, Maan M, et al

All content on Ground Truthsits newsletters, analyses, and podcasts, are free, open-access

The most recent iteration, AG1 Next Gen, was released in spring 2025